An open label, interventional controlled pre-post study of the effects of metformin therapy on insulin resistance and body composition in lean vs.obese PCOS patients

PCOS is one of the most common hormonal disorders in women of reproductive age. Insulin resistance is present in 65-95 %of women with PCOS . Half of PCOS patients are obese and obesity plays a critical role in insulin resistance.half of patients have normal BMI and these lean patients also have increased insulin resistance. Several prospective randomised studies have confirmed positive effects of metformin on metabolic derangements, hyperinsulinemia,hyperandrogenemia, blood pressure and clinical pregnancy rates. However, most of studies are limited to obese patients. Therefore evaluating effects of metformin in lean vs obesePCOS patient’s in longitudinal study is needed to confirm its benefits in lean PCOS patients also. Therefore we want to conduct this study as our hypothesis is metformin will significantly improve insulin resistance indices in both lean and obese patients with greater reduction in obese patients. We will recruit PCOD patients and age and BMI Matched healthy control groups for baseline assessment of insulin resistance and body composition and metabolic parameters.Cases will be divided into two groups of lean PCOS and obese PCOS.Cases will undergo lifestyle intervention and six months of metformin therapy. After 6 months , insulin resistance and body composition parameters will be reassessed. Data will be collected and assessed using SPSS. P value of <0.05 will be considered significant.